Novoron Bioscience develops novel therapeutic approaches to address neurological damage or disease in the central nervous system (CNS). Novoron’s unique focus on lipoprotein-receptors (LRP) enables hope for treatment of conditions for which no current therapies exist. Led by the pioneering work of Founder and CEO, Dr. Travis Stiles, the San Diego-based company is currently advancing multiple therapeutics that treat pathologies of the CNS, including multiple sclerosis, spinal cord injuries, and tauopathies such as Alzheimer’s disease. Novoron has been awarded more than $3.5 million in grant funding from the National Institutes of Health for scientific research into these conditions. Beyond the CNS, Novoron’s proprietary LRP-focused drug development platform will facilitate the future development of treatments for other intractable diseases and conditions. For more information, visit novoron.com.